Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

NCT04714697 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

201

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Cancer

Interventions

DRUG: Cabometyx

Sponsor

Asan Medical Center

Collaborators

[object Object]